Adjuvant chemotherapy in small node-negative triple-negative breast cancer

被引：29

作者：

Steenbruggen, Tessa G. ^{[1
]}

van Werkhoven, Erik ^{[2
]}

van Ramshorst, Mette S. ^{[1
,3
]}

Dezentje, Vincent O. ^{[1
]}

Kok, Marleen ^{[1
,4
]}

Linn, Sabine C. ^{[1
,5
]}

Siesling, Sabine ^{[6
,7
]}

Sonke, Gabe S. ^{[1
]}

机构：

[1] Netherlands Canc Inst, Dept Med Oncol, POB 90203, NL-1006 BE Amsterdam, Netherlands

[2] Netherlands Canc Inst, Dept Biometr, POB 90203, NL-1006 BE Amsterdam, Netherlands

[3] Onze Lieve Vrouw Hosp, Dept Internal Med, Postbus 95500, NL-1090 HM Amsterdam, Netherlands

[4] Netherlands Canc Inst, Dept Tumor & Biol Immunol, POB 90203, NL-1006 BE Amsterdam, Netherlands

[5] Univ Med Ctr Utrecht, Dept Mol Pathol, POB 85500, NL-3508 GA Utrecht, Netherlands

[6] Netherlands Comprehens Canc Org, Dept Res & Dev, POB 19079, NL-3501 DB Utrecht, Netherlands

[7] Univ Twente, Dept Hlth Technol & Serv Res, Tech Med Ctr, POB 217, NL-7500 AE Enschede, Netherlands

来源：

EUROPEAN JOURNAL OF CANCER | 2020年 / 135卷

关键词：

Adjuvant chemotherapy; Triple-negative breast cancer; Axillary lymph node-negative; TUMOR-INFILTRATING LYMPHOCYTES; GENE-EXPRESSION; SURVIVAL; OUTCOMES; BRCA2; EFFICACY; INVASION; FEATURES; CARRIERS; SUBTYPE;

D O I：

10.1016/j.ejca.2020.04.033

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Recommendations on adjuvant chemotherapy in pT1N0M0 triple-negative breast cancer (TNBC) differ among international guidelines owing to lack of randomized trial data. We evaluated associations of adjuvant chemotherapy with a long-term outcome in a population-based cohort of pT1N0M0 TNBC. Methods: All patients diagnosed with pT1N0M0 TNBC in the Netherlands between 2005 and 2016 were identified from the Netherlands Cancer Registry. Patient, tumour and treatment characteristics were recorded. The date and cause of death were obtained from Statistics Netherlands. We used multivariable Cox regression models to evaluate associations of adjuvant chemotherapy with breast cancer-specific survival (BCSS) and overall survival (OS), adjusted for baseline characteristics and performed sensitivity analyses using propensity score (PS) weighting. Results: We identified 4366 patients: 284 with pT1a, 923 with pT1b and 3159 with pT1c tumours. Adjuvant chemotherapy was administered in 53% of patients. Patients receiving chemotherapy had more unfavourable baseline characteristics including younger age, larger tumours and higher tumour grade. At 8.2 years median follow-up (interquartile range = 5.8-10.9), 671 patients had died, of whom 311 because of breast cancer. After adjustment for baseline characteristics, chemotherapy was associated with improved BCSS (adjusted hazard ratio [aHR] = 0.65; 95% confidence interval [CI] = 0.48-0.89). The effect of chemotherapy differed by tumour size (pT1a: aHR = 4.28, 95% CI = 1.12-16.44; pT1b: aHR = 1.12, 95% CI = 0.51-2.49; pT1c: aHR = 0.60, 95% CI = 0.43-0.82; p(interaction) = 0.02). Findings for OS were in line with BCSS results. PS-weighting analysis confirmed the results of the primary analysis. Conclusions: Adjuvant chemotherapy is associated with better BCSS and OS in pT1N0M0 TNBC. Better outcome is most evident in pT1c tumours and may not outweigh harm in pT1a/pT1b tumours. (C) 2020 Elsevier Ltd. All rights reserved.

引用

页码：66 / 74

页数：9

共 43 条

[1] Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis [J].

Austin, Peter C. .

STATISTICS IN MEDICINE, 2016, 35 (30) :5642-5655

[2] Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies [J].

Austin, Peter C. ;

Stuart, Elizabeth A. .

STATISTICS IN MEDICINE, 2015, 34 (28) :3661-3679

[3] Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis [J].

Baretta, Zora ;

Mocellin, Simone ;

Goldin, Elena ;

Olopade, Olufunmilayo I. ;

Huo, Dezheng .

MEDICINE, 2016, 95 (40)

[4] 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer [J].

Cardoso, F. ;

van't Veer, L. J. ;

Bogaerts, J. ;

Slaets, L. ;

Viale, G. ;

Delaloge, S. ;

Pierga, J. -Y. ;

Brain, E. ;

Causeret, S. ;

DeLorenzi, M. ;

Glas, A. M. ;

Golfinopoulos, V. ;

Goulioti, T. ;

Knox, S. ;

Matos, E. ;

Meulemans, B. ;

Neijenhuis, P. A. ;

Nitz, U. ;

Passalacqua, R. ;

Ravdin, P. ;

Rubio, I. T. ;

Saghatchian, M. ;

Smilde, T. J. ;

Sotiriou, C. ;

Stork, L. ;

Straehle, C. ;

Thomas, G. ;

Thompson, A. M. ;

van der Hoeven, J. M. ;

Vuylsteke, P. ;

Bernards, R. ;

Tryfonidis, K. ;

Rutgers, E. ;

Piccart, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08) :717-729

[5] Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 [J].

Coates, A. S. ;

Winer, E. P. ;

Goldhirsch, A. ;

Gelber, R. D. ;

Gnant, M. ;

Piccart-Gebhart, M. ;

Thuerlimann, B. ;

Senn, H. -J. .

ANNALS OF ONCOLOGY, 2015, 26 (08) :1533-1546

[6] Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer [J].

Colleoni, M. ;

Rotmensz, N. ;

Maisonneuve, P. ;

Sonzogni, A. ;

Pruneri, G. ;

Casadio, C. ;

Luini, A. ;

Veronesi, P. ;

Intra, M. ;

Galimberti, V. ;

Torrisi, R. ;

Andrighetto, S. ;

Ghisini, R. ;

Goldhirsch, A. . ;

Viale, G. .

ANNALS OF ONCOLOGY, 2007, 18 (10) :1632-1640

[7] Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials [J].

Davies, C. ;

Godwin, J. ;

Gray, R. ;

Clarke, M. ;

Darby, S. ;

McGale, P. ;

Wang, Y. C. ;

Peto, R. ;

Pan, H. C. ;

Cutter, D. ;

Taylor, C. ;

Ingle, J. .

LANCET, 2011, 378 (9793) :771-784

[8] Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study [J].

de Nonneville, A. ;

Goncalves, A. ;

Zemmour, C. ;

Cohen, M. ;

Classe, J. M. ;

Reyal, F. ;

Colombo, P. E. ;

Jouve, E. ;

Giard, S. ;

Barranger, E. ;

Sabatier, R. ;

Bertucci, F. ;

Boher, J. M. ;

Houvenaeghel, G. .

EUROPEAN JOURNAL OF CANCER, 2017, 84 :34-43

[9] Comparing causes of death of Hodgkin lymphoma and breast cancer patients between medical records and cause-of-death statistics [J].

de Vries, Simone ;

Schaapveld, Michael ;

Kardaun, Jan W. P. F. ;

de Bruin, Kim H. ;

Krol, Augustinus D. G. ;

Lugtenburg, Pieternella J. ;

Jacobse, Judy N. ;

Aleman, Berthe M. P. ;

van Leeuwen, Flora E. .

CLINICAL EPIDEMIOLOGY, 2018, 10 :1523-1531

[10] Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers [J].

Denkert, Carsten ;

von Minckwitz, Gunter ;

Brase, Jan C. ;

Sinn, Bruno V. ;

Gade, Stephan ;

Kronenwett, Ralf ;

Pfitzner, Berit M. ;

Salat, Christoph ;

Loi, Sherene ;

Schmitt, Wolfgang D. ;

Schem, Christian ;

Fisch, Karin ;

Darb-Esfahani, Silvia ;

Mehta, Keyur ;

Sotiriou, Christos ;

Wienert, Stephan ;

Klare, Peter ;

Andre, Fabrice ;

Klauschen, Frederick ;

Blohmer, Jens-Uwe ;

Krappmann, Kristin ;

Schmidt, Marcus ;

Tesch, Hans ;

Kuemmel, Sherko ;

Sinn, Peter ;

Jackisch, Christian ;

Dietel, Manfred ;

Reimer, Toralf ;

Untch, Michael ;

Loibl, Sibylle .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (09) :983-991

← 1 2 3 4 5 →